Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.
Anthony D. Elias, MD
Advertisement
Articles by Anthony D. Elias, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
3
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
4
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
5